00:17:56 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2025-02-26 Bokslutskommuniké 2024
2024-11-22 Kvartalsrapport 2024-Q3
2024-08-22 Kvartalsrapport 2024-Q2
2024-05-30 X-dag ordinarie utdelning PMDS 0.00 SEK
2024-05-29 Årsstämma 2024
2024-05-28 Kvartalsrapport 2024-Q1
2024-04-03 Extra Bolagsstämma 2024
2024-02-29 Bokslutskommuniké 2023
2024-01-31 Split PMDS 128:1
2023-12-29 Extra Bolagsstämma 2023
2023-11-28 Kvartalsrapport 2023-Q3
2023-08-30 Kvartalsrapport 2023-Q2
2023-06-27 Årsstämma 2023
2023-05-24 X-dag ordinarie utdelning PMDS 0.00 SEK
2023-05-23 Kvartalsrapport 2023-Q1
2023-02-28 Bokslutskommuniké 2022
2022-11-29 Kvartalsrapport 2022-Q3
2022-08-30 Kvartalsrapport 2022-Q2
2022-05-19 X-dag ordinarie utdelning PMDS 0.00 SEK
2022-05-17 Kvartalsrapport 2022-Q1
2022-05-17 Årsstämma 2022
2022-02-16 Bokslutskommuniké 2021
2021-11-23 Kvartalsrapport 2021-Q3
2021-08-24 Kvartalsrapport 2021-Q2
2021-05-28 X-dag ordinarie utdelning PMDS 0.00 SEK
2021-05-27 Extra Bolagsstämma 2021
2021-05-27 Kvartalsrapport 2021-Q1
2021-05-27 Årsstämma 2021
2021-02-23 Bokslutskommuniké 2020
2020-11-24 Kvartalsrapport 2020-Q3
2020-08-25 Kvartalsrapport 2020-Q2
2020-05-27 X-dag ordinarie utdelning PMDS 0.00 SEK
2020-05-26 Årsstämma 2020
2020-05-26 Kvartalsrapport 2020-Q1
2020-02-18 Bokslutskommuniké 2019
2019-11-22 Kvartalsrapport 2019-Q3
2019-10-22 Extra Bolagsstämma 2019
2019-08-27 Kvartalsrapport 2019-Q2
2019-05-22 X-dag ordinarie utdelning PMDS 0.00 SEK
2019-05-21 Kvartalsrapport 2019-Q1
2019-05-21 Årsstämma 2019
2019-02-26 Bokslutskommuniké 2018
2018-11-23 Kvartalsrapport 2018-Q3
2018-08-20 Kvartalsrapport 2018-Q2
2018-05-17 X-dag ordinarie utdelning PMDS 0.00 SEK
2018-05-16 Årsstämma 2018
2018-05-16 Kvartalsrapport 2018-Q1
2018-02-06 Bokslutskommuniké 2017
2017-11-21 Kvartalsrapport 2017-Q3
2017-08-30 Kvartalsrapport 2017-Q2

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
PMD Device Solutions utvecklar och säljer medicinska produkter för andningsövervakning, för både sjukhus och hemvård. Dess primära produkt är RespiraSense, en lösning som används för att övervaka andningsfrekvensen och stödja upptäckten av patientförsämring, och för att undvika andningssvikt och ogynnsamma patientresultat. RespiraSense kommersialiseras i Europa, Storbritannien och är FDA godkänd i USA.
2024-06-28 11:27:00

The Annual General Meeting of PMD Device Solutions AB (publ), reg. no 556639–6809 (the "Company") was held today, 28 June 2024. The Meeting resolved on all proposed matters in accordance with the Board's previously announced proposals. The following is a summary of the main decisions taken.

Adoption of the profit and loss account and balance sheet

The Annual General Meeting adopted the income statement and balance sheet as included in the annual report and consolidated financial statements for the financial year 2023.

Appropriations relating to the result

The Annual General Meeting decided that the result for the financial year 2023 shall be carried forward.

Discharge from liability

The Annual General Meeting resolved to discharge each of the members of the Board of Directors and the CEO from liability in respect of the management of the financial year 2023.

Board of Directors and auditor

The Annual General Meeting resolved, in accordance with the proposals submitted, that a total Board fee of SEK 844,800 shall be paid, of which SEK 316,800 to the Chairman of the Board and SEK 264,000 each to the Board members Christer Ahlberg and Magnus Christensen.

It was resolved that the auditor's fee shall be paid according to current and approved invoices.

It was resolved that the Board shall consist of five members and to re-elect Myles Murray, Christer Ahlberg, Magnus Christensen and Anne Dorney as ordinary members of the Board. It was decided to elect Peter Donnelly as Chairman of the Board.

It was further resolved to appoint, until the end of the next Annual General Meeting, the authorized public accountant Martin Gustafsson, HLB Auditoriet AB, as the Company's auditor with authorized public accountant Mats-Åke Andersson as deputy auditor.

Authorisation for the Board of Directors to decide on the issue of shares, warrants and convertibles

The Annual General Meeting decided to authorise the Board of Directors to resolve, on one or more occasions during the period until the next Annual General Meeting, to issue new shares, convertibles and warrants with or without derogation from the shareholders' preferential rights. New issues of shares, as well as issues of warrants and convertibles, may be made with or without deviation from the shareholders' preferential rights and with or without provision for contribution in kind, set-off or other conditions.

Issues with or without derogation from the shareholders' preferential rights may be made to the extent permitted by the current Articles of Association, or by any other Articles of Association that the shareholders may adopt by the required majority during the period up to the next Annual General Meeting.

The issue decided by virtue of the authorisation shall be made at the market subscription price, subject to the market issue discount, if any. The issue decided by virtue of the authorisation shall be made in order to provide the Company with working capital, to increase the Company's financial flexibility and to enable acquisitions by payment in shares.